|  |
| --- |
| **The Basic Principles of Biomedical and Medical Science Study Designs** |

**Alphonsus Ogbonna Ogbuabor1**

1Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, College of Health Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria; Editorial Board Member “The Medical Bulletin”

|  |  |
| --- | --- |
| **Editorial** | **Abstract:** **DOI:**  |
| ***\*Corresponding Author:***Alphonsus Ogbonna Ogbuabor***Citation:***Alphonsus Ogbonna Ogbuabor. (2023); The Basic Principles of Biomedical and Medical Science Study Designs. iraetc med. bull; 1(1) 1-5.This work is licensed under a Creative Commons Attribution- NonCommercial 4.0 International license. | ***Background***: **(10Bold)** The spinal cord has taken the center stage in analgesia practice and Spinal anaesthesia is the commonly used technique for lower limb surgeries as it is easy to administer, economical and causes less hemodynamic variation than general anaesthesia. Hence different additives can be used to increase the duration of postoperative analgesia. Since there are no studies comparing Buprenorphine and Nalbuphine, we have selected this study to evaluate the effect of intrathecal Bupivacaine with Buprenorphine compared with Nalbuphine for postoperative analgesia. (10) ***Materials and Methods***Group A (Bupivacaine and Nalbuphine) and Group B (Bupivacaine and Buprenorphine). Group A received 2.8ml of 0.5%(H)Bupivacaine+[0.2 ml (2mg) of Nalbuphine (undiluted) taken in 1ml tuberculin syringe 1mg/0.1ml] and group B received 2.8ml of 0.5%(H)Bupivacaine+0.2ml(60µg) of buprenorphine for spinal anaesthesia. The onset and duration of sensory and motor blockade, 2 segment regression, duration of postoperative analgesia, side-effects and haemodynamic parameters were compared between the groups. (10) ***Results****:* The duration of postoperative analgesia was significantly prolonged with Buprenorphine compared to Nalbuphine with Bupivacaine (p<0.05). (10) ***Conclusion:*** *D*uration of postoperative analgesia when compared to intrathecal Bupivacaine with Nalbuphine 2mg.(10)***Key Word****s:***(11Bold)**Key words1; Key words2; Key words3; Key words4. |
| || © IRAETC Publisher **|| Publication History -** Received: 02.01.2023 || Accepted: 28.01.2023 || Published: 02.02.2023||  |

1. **Introduction (11 Bold)**

 Numerous epidemiological studies and randomized controlled trials have documented the association between elevated LDL-C levels with increased CVD risk in both diabetic and non diabetic populations.6,7. Thus reducing LDL-C levels is the primary goal of therapy for diabetic dyslipidemia.5,8.Statins are considered the first pharmacological line of treatment of dyslipidemia in diabetic patients9. Lowering of LDL-C levels is thought to be the main beneficial effect of statin treatment.In India currently no guidelines available for treating diabetic dyslipidemia and no previous study has documented the efficacy.The current study aims to build growing awareness of atherosclerosis specific care of diabetes patient by examining efficacy of two most commonly prescribed statins in India.(10)

1. **Material And Methods (11 Bold)**

Department of general Medicine at Dr. Ram Manohar Lohia Combined Hospital, Vibhuti Khand, Gomti Nagar, Lucknow, Uttar Pradesh from November 2014 to November 2015. A total 300 adult subjects (both male and females) of aged ≥ 18, years were for in this study.(10)

**Study Design:** Prospective open label observational study

**Study Location**: General Medicine, at Dr. Ram Manohar Lohia Combined Hospital, Vibhuti Khand, Gomti Nagar, Lucknow, Uttar Pradesh.(10)

**Study Duration:** November 2014 to November 2015.

**Sample size:** 300 patients.

**Sample size calculation:** The target population from which we randomly selected our sample was considered 20,000. We assumed that the confidence interval of 10% and confidencelevel of 95%. The sample size actually obtained for this study was 96 patients for each group. We planned to include 300 patients (Group I- Control, Group II- Cases of 100 patients for each group) with 4% drop out rate.(10)

**Subjects & selection method**: Were prescribed the indicated statins and underwent fasting blood test of lipid profile before statin treatment initiation between from November 2014 to November 2015. Patients were divided into three groups (each group had 100 patients) according to doses of statins. The prescribed doses of statin in RMLH for diabetic patients (10)

With dyslipidemia were as follows:

Group A(N=100 patients) -Atorvaststin 40mg daily to each patients;

Group B (N=100 patients) -Rosuvastatin 20mg daily to each patients; and

Group C (N=100 patients) **-**Rosuvastatin 20 mg to each patients at alternative days.

**Inclusion criteria:** (10 Bold)

1. Aged ≥ 18 years,
2. Patients have a total cholesterol level of ≥154.68 mg/dl , LDL-C 96.6 mg/dl, HDL-C ≤ 138.6 in men and ≤46.3 mg/dl in women.
3. Fasting triglycerides ≥ 150.56 mg/dl, obtained within 1 week before the first use of statins which was then compared at first- and second-year intervals.(10)

**Exclusion criteria:** (10 Bold)

1. Patients with previous history of angina, severe vascular disease, or other life threatening disease.
2. Patients with nephropathy and/or hypothyroidism, active liver disease, bile duct problems, or ALT > 3 × ULN.
3. Patients with creatine kinase levels > 10 × ULN.
4. Patients taking concurrent corticosteroids, ciclosporin, and/or hormone replacement therapy.
5. Patients who are physically inactive.
6. Patients with a history of drug or alcohol abuse.(10)

**Procedure methodology** (10 Bold)

The questionnaire included socio-demographic characteristics such as age, gender, nationality, height, weight, and consanguineous marriage, physical activity and lifestyle habits like smoking and alcohol and statin prescribed for at least 2 years continuously and dose, type of DM, its duration, and clinical and biochemistry laboratory investigations such as fasting bloodglucose, glycated hemoglobin (HbA1C), total cholesterol, HDL and LDL cholesterol levels, and TGs.(10)

Cholesterol and TG quantization was determined by enzymatic assay. LDL-C was calculated using the Friedewal dequation for patients with TG ≤ 400 mg/dl and measured by b-quantification for those with TG > 400 mg/dl. Levels of non-HDL-C were calculated by subtraction of HDL-C from total cholesterol.(10)

was taken from the pharmacy database. Baseline characteristics of the patients were collected from the database 1 week before the first use of statins. . Height and weight were measured using standardized method. The body mass index (BMI) was calculated as the weight in kilograms (with) divided by height in meters squared.(10)

Blood pressure was recorded using an electronic instrument (Model: HEM-7101, Omron Corporation, Tokyo, Japan) as the mean of two readings taken five minutes apart.(10)

**The prescribed doses of statin in RMLH for diabetic patients with dyslipidemia wereas follows:** (10 Bold)

**Group A-**Atorvaststin 40mg;

**Group B** -Rosuvastatin 20mg; and

**Group C -**Rosuvastatin 20 mg at alternate days.(10)

Fasting capillary blood glucose [CBG] was determined by using One Touch Ultra glucose meter (Johnson & Johnson, Milpitas, California) after eight hours of overnight fasting. A fasting venous sample was collected and lipids were measured. (10)

All biochemical assays was carried out by the same team of laboratory technicians using the same method, throughout the study period. The samples were assayed for total cholesterol, triglycerides and HDL cholesterol.

Serum cholesterol (cholesterol esterase oxidase-peroxidase-amidopyrine method), serum triglycerides (glycerol phosphate was measured using the Beckman Coulter AU 2700/480 Autoanalyser (Beckm an AU [Olympus], Ireland). The intra– and inter-assay coefficients of variants (CV) for the biochemical assays ranged from 3.1% to 7.6%. (10)

In every subject, a semi-quantitative food frequency questionnaire was administered to collect detailed information on dietary intake over the past year. Dietary fat and oil intake was assessed as the amount of fat/oil used during cooking and/or added at the table.

**Statistical analysis** (10 Bold)

Data was used to determine the difference between baseline and 2 years after regarding biochemistry parameters, and this was confirmed by the Wilcoxon test which wasa nonparametric test that compares two paired groups. Chi-square and Fisher exact tests were performed to test for differences in proportions of categorical variables between two or more groups. The level *P* < 0.05 was considered as the cutoff value or significance.(10)

1. **Result (11 Bold)**

Atorvastatin 40 mg,-37.28% on Rosuvastatin 20 mg daily and -37.53% on Rosuvastatin 20 mg alternate day.

The total Cholestrol level reduced by -14.71%,17.35%,-11.63%,respectively.

Trigyceride level reduced by -14.71%,17.3%,11.^3%, respectively.

Non HDL-C went down by -37.32%,29.715% and -29.71% respectively.

HDL-C improved by +3.46%,+8.17%and 8.17%,respectively. (10)

Table no 1 LDL-C, 158.3 ±22.6 mg/dl, 156.1 ±27.8&157.2 ±26.7 mg/dl, HDL-C, 37.5 ±2.70 mg/dl, 35.5 ±2.21&36.4 ±1.90 mg/dl, Triglyceride165.8 ±30.8 mg/dl, 162.6 ±28.2&166.8 ±35.7mg/dl, Non-HDL-C 180.6 ±31.2 mg/dl, 182.4 ±29.2 & 185.2 ±32.4 mg/dl, , FBG, 142.5 ±25.7 mg/dl, 148.2 ±26.9 & 145.8 ±27. mg/dl4, HbA1c, %, 5.82 ±0.2, 5.62±0.4 & 5.65 ±0.3 respectively of patients of the three groups. The difference in the values of all parameters in respect of three groups was not statistically significant (p>0.05) (10)

**Table no 1** (10 Bold)**:** Shows metabolic parameters of patients of the three groups before treatment. (10)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Atorvastatin 40 mg | Rosuvastatin 20mg | Rosuvastatin 20 mg alternate day | P value (I to II) | P value (I to III) | P value (II to III) |
| Lipids, mg/dL |  |  |  |  |  |  |
| Total Cholesterol (TC) | 224.3±30.8 | 226.1±35.4 | 225.3±40.7 | 0.7017 | 0.8449 | 0.8449 |
| LDL-C | 158.3±22.6 | 156.1±27.8 | 157.2±26.7 | 0.5399 | 0.7535 | 0.7757 |
| HDL-C | 37.5±8.70 | 35.5±9.21 | 36.4±7.90 | 0.357 |  0.487 |  0.389 |
| Triglyceride | 165.8±30.8 | 162.6±28.2 | 166.8±35.7 |  0.4444 | 0.8323 | 0.3570 |
| Non-HDL-C | 180.6±31.2 | 182.4±29.2 | 185.2±32.4 | 0.6740 | 0.3077 | 0.5216 |
|  |  |  |  |  |  |  |
|  |  |  |  |   |  |  |
| Glucose and HbA1C |  |  |  |  |  |  |
| FBG, mg/dL | 142.5±25.7 | 148.2±26.9 | 145.8±27.4 | 0.1271 | 0.3808 |  0.5327 |
| HbA1c, % | 5.82±0.2 | 5.62±0.4 | 5.65±0.3 | 0.265 |  0.357 |  0.647 |

Table Size (8)



**Follow up after 6 weeks** (10)

Table no 2: While there had been a reduction in the undesirable Lipids, as above, due to the above medication ,there was a positive upwards change in the desirable lipids like high-density lipoprotein cholesterol (HDL-C) which improved by(+3.46%).Further, Fasting blood glucose (FBG) mg/dL level were reduced by (-36.17%).and HbA1c, % hemoglobin A1C test which measures blood sugar control over the preceding three months had also gone down by( -1.89%). The desirable alterations in respect of all the above parameters after 6 weeks of medication which are attributable to the above medication, were highly statistically significant, P<0.001 except HbA1c .

**Table no2** (10 Bold)**:** Records the Percent Change in Lipids profile after treatment given. (10)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Atorvastatin 40 mg(before) | Atorvastatin 40 mg(After) | Percentage Change | P value |
| Lipids, mg/dL |  |  |  |  |
| Total Cholesterol (TC) | 224.3±30.8 | 150.7±22.2 | -32.81% | <0.001 |
| LDL-C | 158.3±22.6 | 83.9±15.1 | -46.99% | <0.001 |
| HDL-C | 37.5±2.70 | 38.8±3.5 | +3.46% | 0.003 |
| Triglyceride | 165.8±30.8 | 141.4±22.6 | -14.71% | <0.001 |
| Non-HDL-C | 180.6±31.2 | 113.2±18.1 | -37.32% | <0.001 |
| Glucose and HbA1C |  |  |  |  |
| FBG, mg/dL | 142.5±25.7 | 90.95±7.9 | -36.17% | <0.001 |
| HbA1c, % | 5.82±0.2 | 5.71±0.3 | -1.89% | 0.198 |

Table Size (8)



**Table no3:** Shows Percent Change went down by(-29.71%),after 6 weeks of medication. While there had been a reduction in the undesirable Lipids due to the above medication ,there was a positive upwards change in the desirable Lipids like high-density lipoprotein cholesterol (HDL-C) which improved by (+8.17%), Further, Fasting blood glucose, FBG, mg/dL level were reduced by (-37.95%). and HbA1c, % hemoglobin A1C test which measures blood sugar control over the preceding three months had also gone down by(-11.00%). The desirable alterations in respect of all the above parameters which were attributable to the above medication, were statistically significant, P<0.001---0.033.

**Table no 3** (10 Bold)**:** Shows Percent Change in Lipids,( mg/dL) on a regular dose of Rosuvastatin 20mg for 6 weeks**.** (10)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Rosuvastatin 20mg(before) | Rosuvastatin 20mg(After) | Percentage Change | P value |
| Lipids, mg/dL |  |  |  |  |
| Total Cholesterol (TC) | 226.1±35.4 | 166.2±25.7 | -26.49% | <0.001 |
| LDL-C | 156.1±27.8 | 97.9±14.7 | -37.28% | <0.001 |
| HDL-C | 35.5±2.21 | 38.4±3.6 | +8.17% | <0.001 |
| Triglyceride | 164.6±28.2 | 136.2±23.4 | -17.3% | <0.001 |
| Non-HDL-C | 182.4±29.2 | 128.2±20.5 | -29.71% | <0.001 |
| Glucose and HbA1C |  |  |  |  |
| FBG, mg/dL | 148.2±26.9 | 91.95±8.8 | -37.95% | <0.001 |
| HbA1c, % | 5.62±0.4 | 5.5±0.2 | -2.13% | 0.187 |

Table Size (8)



C went down by (-29.71%),. While there had been a reduction in the undesirable Lipids due to the above medication ,there was a positive upwards change in the desirable Lipids like high-density lipoprotein cholesterol (HDL-C) which improved by(+8.17%), Further, Fasting blood glucose, FBG, mg/dL level were reduced by (-36.65%). and HbA1c, % hemoglobin A1C test which measures blood sugar control over the preceding three months had also gone down by(+4.07%). The desirable changes in respect of all the above parameters attributable to the above medication, were statistically highly significant, P<0.001---0.033 except HbA1c.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Rosuvastatin 20 mg alternate day(before**)** | Rosuvastatin 20 mg alternate day (After**)** | Percentage Change | P value |
| Lipids, mg/dL |  |  |  |  |
| Total Cholesterol (TC) | 225.3±40.7 | 165.9±23.1 | -26.36% | <0.001 |
| LDL-C | 157.2±26.7 | 98.2±16.3 | -37.53% | <0.001 |
| HDL-C | 36.4±1.90 | 38.5±2.9 | +5.76% | < 0.001 |
| Triglyceride | 166.8±35.7 | 140.4±21.9 | -15.83% | <0.001 |
| Non-HDL-C | 185.2±32.4 | 127.2±19.9 | -31.31% | <0.001 |
| Glucose and HbA1C |  |  |  |  |
| FBG, mg/dL | 145.8±27.4 | 92.35±9.6 | -36.65% | <0.001 |
| HbA1c, % | 5.65±0.3 | 5.66±0.4 | +0.17% | 0.287 |

Table Size (8)



Table no 5 Shows metabolic parameters of patients of each of the three groups after 6 weeks of treatment. Metabolic parameters of patients of the three patients treated with a regular dose of Atorvastatin 40 mg. In that group of patients the HbA1c, % level was also well within the normal range of4% to 5.6%. The variation in the quantities of Total Cholesterol , LDL-Cand HbA1c, % among the patients of the three groups was statistically significant as P<0.001.(10)

**Table no 5** (10 Bold)**:** Shows metabolic parameters of patients of each of the three groups after 6 weeks of treatment. (10)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Atorvastatin 40 mg | Rosuvastatin 20mg | Rosuvastatin 20 mg alternate day | P value (I to II) | P value (I to III) | P value (II to III) |
| Lipids, mg/dL |  |  |  |  |  |  |
| Total Cholesterol | 150.7±22.2 | 166.2±25.7 | 165.9±23.1 | <0.001 | <0.001 |  0.9309 |
| LDL-C | 83.9±15.1 | 97.9±14.7 | 98.2±16.3 | < 0.001 | < 0.001 | 0.8914 |
| HDL-C | 38.8±3.5 | 38.4±3.6 | 38.5±2.9 | 0.4266 | 0.5100 | 0.8290 |
| Triglyceride | 141.4±22.6 | 146.4±23.4 | 147.4±21.9 |  0.1259 | 0.0580 | 0.7554 |
| Non-HDL-C | 113.2±18.1 | 128.2±20.5 | 127.2±19.9 | < 0.001 | < 0.001 |  0.7267 |
| Glucose and HbA1C |  |  |  |  |  |  |
| Glucose, mg/dL | 90.95±7.9 | 91.95±8.8 | 92.35±9.6 | 0.398 | 0.261 | 0.759 |
| HbA1c, % | 5.71±0.3 | 5.5±0.2 | 5.66±0.4 | 0.013 | 0.010 | 0.056 |

Table Size (8)



Table no 6 National Cholesterol Education Program NCEP ATP III goal. Figures show that while NCEP ATP III goal was achieved by40 (40%) patient treated with a regular dose of Rosuvastatin 20mg, 39 (39%)patient could achieve the goal with an alternate dose of Rosuvastatin 20mg . As for treatment with Atorvastatin 40mgwas concerned only 37 (37%) patient achieved the goal as stipulated by National Cholesterol Education Program NCEP ATP III goal.(10)

**Table no 6** (10 Bold) **:** National Cholesterol Education Program NCEP ATP III goal**.** (10)

|  |
| --- |
| Number of patients (%) achieving NCEP ATP III goal |
|

|  |  |
| --- | --- |
|  Statin therapy |  |

 |

|  |
| --- |
| Achieved (%) |

 | Total |
| Atorvastatin 40mg | 37 (37) | 100 |
| Rosuvastatin 20mg | 40 (40) | 100 |
|  Rosuvastatin 20mg alternate days | 39 (39) | 100 |
| Total | 116(38.66) | 300 |

Table Size (8)



1. **Discussion (11 Bold)**

Dyslipidemia in patients with diabetes plays an important role in development of atherogenesis. The standarded of treatment for dyslipidemia have been statins.For the treatment of dyslipidemia the most commonly used statins are are atorvastatin and rosuvastatin. (10)

The four major statin beneficiary groups have already been defined by NCEP 2013 report.

There is a wealth of evidence suggesting that lowering low density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease (CVD). Both European and US guidelines for CVD prevention recommend the use statins as first-line therapy for dyslipidemia and specify target LDL-C levels. Previously, a National Cholesterol Education Program (NCEP) report had proposed to lower target levels to even more aggressive LDL-C goals for very high-risk patients.

Despite the proven benefits of LDL-C reduction ,lipid managenent is suboptimal and many patients fail to achieve recommended LDL-C goals11,12..Themost likely reasons for this are the use of agents with poor efficacy for LDL-C lowering and suboptimal dose titration.

Such aggressive LDL-C goals,however are harder to achieve. The most effective statin at the lowest dose would represent a simple, effective treatment strategy, enabling more patients to achieve goals without the need for dose titration.

Rosuvastatin, at a dose of 20 mg, has demonstrated high efficacy for LDL-C lowering, enabling patients with hypercholesterolemia to achieve their lipid goals10,11.

Currently no Indian study is available for treating diabetic patients with dyslipidemia or dyslipidemia alone with statin on alternate day and no previous study has documented the efficacy, safety and cost effectiveness of various statins prescribed to diabetic patients. Thus the present study aimed to build on this growing awareness of atherosclerosis-specific care of diabetes patients, by examining efficacy and safety of the two most commonly prescribed statins in India.

The present study was an open label prospective comparative study done in Department of General Medicine, at Dr. Ram Manohar Lohia Combined Hospital a tertiary care teaching hospital,Lucknow, Uttar Pradesh in the time interval of November 2014 to November 2015.. (10)

The study, shows that rosuvastatin (20mg daily and 20mg on alternarnate days) was found to be the most effective statin at reducing LDL-C when compared with atorvastatin (40mg) daily. In other words, rosuvastatin at its lowest dose in this study (20mg) on alternate days was more effective at reducing LDL-C levels than atorvastatin at their higher dose (40mg) daily. Our results are consistent with STELLAR trial which is one of the major open-label, randomized, and multicenter trials to compare rosuvastatin (10, 20, 40, or 80mg) with atorvastatin (10, 20, 40, or 80mg), pravastatin (10, 20, or 40mg), and simvastatin (10, 20, 40, or 80mg) across dose ranges for reduction of LDL-C13. The results of the STELLAR trial revealed that rosuvastatin was consistently, across all doses, the most effective at reducing LDL-C levels in comparison to all of the other statins. (10)

Brunzell JD et al reported the lowering of triglycerides is another important goal in reducing CVD risk among diabetic patients.5 In the present study, the greatest reduction in triglycerides was (−17.3%, *P* < 0.01) and was achieved by patients taking rosuvastatin (20mg daily). This was the case, even in comparison with rosuvastatin 20mg on alternate days and to higher doses of atorvastatin (40mg). However, it is important to note that rosuvastatin (20mg on alternate day) and atorvastatin (40mg) both achieved the second highest reduction in triglycerides (−15.83%, *P* < 0.05, and −14.71%,*P*<0.05), respectively. These findings are similar to the majority of studies in the literature, which have shown a slightly higher reduction in triglycerides in patients taking rosuvastatin in comparison to atorvastatin as reported by Clearfield MB et al.14. It thus appears that, reduction in triglyceride levels is equal with rozuvastatin and atorvastatin in relation to this factor (triglycerides), and that both rosuvastatin and atorvastatin are effective in reducing it.

Raising HDL-C levels is another major factor known to reduce CVD risk. In the present study, all of the statins were found to increase HDL-C levels as has been shown in previous studies. Rosuvastatin (20mg daily) lead to maximal increase (+8.17%). (10)

1. **Conclusion (11 Bold)**

Rosuvastatin 20 mg on every other regimen had equal effect when compared to daily dose regimen of atorvastatin 40 mg &rosuvastatin 20mg.

**References (11 Bold)**

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III) Third report of the national cholesterol education (8)
2. program (NCEP) expert panel on detection, evaluation, and treatment of highblood cholesterol in adults (adult treatment panel III) finalreport. Circulation. 2002;106(25, article 3143).
3. Bener A, Zirie M, Janahi IM, Al-Hamaq AOAA, Musallam M, Wareham NJ.Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factorsin a population-based study of Qatar. Diabetes Research and Clinical Practice. 2009;84(1):99–106.
4. Bener A, Zirie M, Musallam M, Khader YS, Al-Hamaq AOAA. Prevalence ofmetabolic syndrome according to adult treatment panel III and internationaldiabetes federation criteria: a population-based study. Metabolic Syndrome
5. and Related Disorders. 2009;7(3):221–230
6. Bener A, Dafeeah E, Ghuloum S, Al-HamaqAOAA.Association between psychological distress and gastrointestinal symptoms in type 2 diabetes mellitus. World Journal of Diabetes. 2012;3(6):123–129
7. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management inpatients with cardiometabolic risk:consensus statement from the American diabetes association and the american college of cardiology
8. foundation.Diabetes Care. 2008;31(4):811–822
9. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multi centrer trial. The Lancet. 2004; 364(9435) :685–696.
10. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating To new targets (TNT) study.Diabetes Care. 2006;29(6):1220–1226.
11. American Diabetes Association.Standards of medical care in diabetes. Diabetes Care. 2009;32(supplement 1):S13–S61.
12. Henry RR. Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clinical Diabetes.
13. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR\* trial) American Journal of Cardiology.2003;92(2):152–160.
14. Group EUROASPIREIIS: Lifestyle and risk management and use of drug therapies in coronary patients from 15 countries.
15. Principal results from EUROASPIRE II. Eur Heart J 2001,22:554-572.
16. Schuster H, Barter PJ, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, for the MERCURY I Study Group: Effects ofswitching statins on achievement of lipid goals: MeasuringEffective Reductions in holesterol
17. Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004,147:705-713.
18. Pharmaceutical Management Agency. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. (8)